Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: An indirect treatment comparison

AIM To compare the efficacy of tirzepatide 10 and 15 mg with semaglutide 2.4 mg using an indirect treatment comparison. MATERIALS AND METHODS Using SURMOUNT-1 and STEP 1 trial data, mean percentage change in body weight from baseline and odds ratio (OR) of achieving 5% or greater weight loss were compared between tirzepatide 10 and 15 mg at week 72 and semaglutide 2.4 mg at week 68 using matching-adjusted indirect comparison of the efficacy estimand. Sensitivity analyses were completed using different methods, including the Bucher method, also using different estimands and/or time points. RESULTS Greater reductions in percentage change in body weight were observed with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg (tirzepatide 10 mg mean difference: -4.67% [95% CI -5.91%, -3.43%]; tirzepatide 15 mg mean difference: -5.92% [95% CI -7.16%, -4.68%]; both P < .001). Similarly, more participants achieved 5% or greater weight loss with tirzepatide 10 mg (OR 2.61 [95% CI 1.48, 4.57]; P < .001) and 15 mg (OR 2.75 [95% CI 1.57, 4.81]; P < .001) compared with semaglutide 2.4 mg. All sensitivity analyses were consistent, except for an OR of achieving 5% or greater weight loss with tirzepatide 10 mg using the Bucher method to analyse the treatment regimen estimand (P = .074). CONCLUSIONS Currently there are no direct comparisons of tirzepatide and semaglutide for weight management. Using the matching-adjusted indirect treatment comparison method to compare the efficacy of tirzepatide and semaglutide for chronic weight management, this analysis showed greater weight loss with tirzepatide 10 and 15 mg versus semaglutide 2.4 mg.

[1]  K. Zaletel,et al.  Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity , 2022, Diabetes, obesity & metabolism.

[2]  C. Bailey,et al.  Tirzepatide for the treatment of adults with type 2 diabetes: An endocrine perspective , 2022, Diabetes, obesity & metabolism.

[3]  K. Pantalone,et al.  Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison , 2022, Diabetes, obesity & metabolism.

[4]  N. Iyer,et al.  Impact of Sustained Weight Loss on Cardiometabolic Outcomes. , 2021, The American journal of cardiology.

[5]  T. Wadden,et al.  Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1) , 2021, Journal of the Endocrine Society.

[6]  D. Skovgaard,et al.  The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity , 2020, Diabetes, obesity & metabolism.

[7]  M. Nauck,et al.  The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 (GLP‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long‐acting GLP‐1 receptor agonists , 2020, Diabetes, obesity & metabolism.

[8]  M. Coghlan,et al.  How May GIP Enhance the Therapeutic Efficacy of GLP-1? , 2020, Trends in Endocrinology & Metabolism.

[9]  G. Yeo,et al.  Glucose-Dependent Insulinotropic Polypeptide Receptor-Expressing Cells in the Hypothalamus Regulate Food Intake , 2019, Cell metabolism.

[10]  F. Reimann,et al.  The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system , 2019, Peptides.

[11]  R. Gimeno,et al.  LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept , 2018, Molecular metabolism.

[12]  M. Horowitz,et al.  Upper and/or lower gastrointestinal adverse events with glucagon‐like peptide‐1 receptor agonists: Incidence and consequences , 2017, Diabetes, obesity & metabolism.

[13]  Mei Lu,et al.  Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[14]  Joseph C Cappelleri,et al.  Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[15]  David C Hoaglin,et al.  Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[16]  J. Holst The physiology of glucagon-like peptide 1. , 2007, Physiological reviews.

[17]  F. Greenway,et al.  Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes The STEP 8 Randomized Clinical Trial , 2021 .